Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Cancers 2013, 5(3), 815-837; doi:10.3390/cancers5030815
Review

Lentiviral Vectors for Cancer Immunotherapy and Clinical Applications

1,* , 1,2
 and 1,2
Received: 10 May 2013; in revised form: 7 June 2013 / Accepted: 21 June 2013 / Published: 2 July 2013
(This article belongs to the Special Issue Cancers Gene Therapy)
View Full-Text   |   Download PDF [584 KB, uploaded 2 July 2013]
Abstract: The success of immunotherapy against infectious diseases has shown us the powerful potential that such a treatment offers, and substantial work has been done to apply this strategy in the fight against cancer. Cancer is however a fiercer opponent than pathogen-caused diseases due to natural tolerance towards tumour associated antigens and tumour-induced immunosuppression. Recent gene therapy clinical trials with viral vectors have shown clinical efficacy in the correction of genetic diseases, HIV and cancer. The first successful gene therapy clinical trials were carried out with onco(g-)retroviral vectors but oncogenesis by insertional mutagenesis appeared as a serious complication. Lentiviral vectors have emerged as a potentially safer strategy, and recently the first clinical trial of patients with advanced leukemia using lentiviral vectors has proven successful. Additionally, therapeutic lentivectors have shown clinical efficacy for the treatment of HIV, X-linked adrenoleukodystrophy, and b-thalassaemia. This review aims at describing lentivectors and how they can be utilized to boost anti-tumour immune responses by manipulating the effector immune cells.
Keywords: lentiviral vector; cancer immunotherapy; gene therapy; antigen presentation; dendritic cells lentiviral vector; cancer immunotherapy; gene therapy; antigen presentation; dendritic cells
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Liechtenstein, T.; Perez-Janices, N.; Escors, D. Lentiviral Vectors for Cancer Immunotherapy and Clinical Applications. Cancers 2013, 5, 815-837.

AMA Style

Liechtenstein T, Perez-Janices N, Escors D. Lentiviral Vectors for Cancer Immunotherapy and Clinical Applications. Cancers. 2013; 5(3):815-837.

Chicago/Turabian Style

Liechtenstein, Therese; Perez-Janices, Noemi; Escors, David. 2013. "Lentiviral Vectors for Cancer Immunotherapy and Clinical Applications." Cancers 5, no. 3: 815-837.



Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert